Published in J Clin Invest on November 01, 2004
Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med (2005) 3.48
Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med (2006) 2.08
An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest (2004) 1.69
Expression of CCR8 is increased in asthma. Clin Exp Allergy (2010) 1.51
IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses. J Exp Med (2006) 1.36
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood (2009) 1.35
Role of regulatory T cells during virus infection. Immunol Rev (2013) 1.28
Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol (2007) 1.27
Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol (2010) 1.23
Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest (2006) 1.21
Macrophages: regulators of sex differences in asthma? Am J Respir Cell Mol Biol (2009) 1.15
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 1.12
Human dendritic cell subsets for vaccination. J Clin Immunol (2005) 1.09
Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India (2015) 1.07
Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms. J Allergy Clin Immunol (2015) 1.07
Mode of delivery and cord blood cytokines: a birth cohort study. Clin Mol Allergy (2006) 1.07
Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy (2010) 1.06
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest (2014) 1.03
Deficiency of endothelial heparan sulfates attenuates allergic airway inflammation. J Immunol (2009) 1.00
Perinatal immunotoxicity: why adult exposure assessment fails to predict risk. Environ Health Perspect (2006) 0.98
Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol (2010) 0.96
Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Allergic and Infectious Disease Pathology (II). Evid Based Complement Alternat Med (2006) 0.94
Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells. J Control Release (2012) 0.94
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 0.94
The asthma epidemic and our artificial habitats. BMC Pulm Med (2005) 0.89
Autoimmune pancreatitis--a new evolving pancreatic disease? Langenbecks Arch Surg (2010) 0.88
Toxoplasma gondii infection blocks the development of allergic airway inflammation in BALB/c mice. Clin Exp Immunol (2008) 0.88
Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol (2010) 0.87
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy (2012) 0.87
Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39. BMC Med Genet (2014) 0.86
Regulatory T cells in type 1 autoimmune pancreatitis. Int J Rheumatol (2012) 0.85
Relationship between maternal and child cytokine responses to allergen and phytohaemagglutinin 2 years after delivery. Clin Exp Immunol (2006) 0.85
A role for CXCL13 (BCA-1) in pregnancy and intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med (2008) 0.85
Histamine H1-receptor antagonists with immunomodulating activities: potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin Exp Immunol (2009) 0.85
STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation. J Immunol (2013) 0.85
Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand. J Allergy Clin Immunol (2016) 0.84
Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol (2007) 0.84
Primary sclerosing cholangitis with elevated serum IgG4 levels and/or infiltration of abundant IgG4-positive plasma cells. J Gastroenterol (2009) 0.83
Antibody and cytokine responses to house dust mite allergens and Toxoplasma gondii antigens in atopic and non-atopic Brazilian subjects. Clin Immunol (2010) 0.83
Modulation of immune function by polyphenols: possible contribution of epigenetic factors. Nutrients (2013) 0.82
Bacillus Calmette-Guérin Suppresses Asthmatic Responses via CD4(+)CD25(+) Regulatory T Cells and Dendritic Cells. Allergy Asthma Immunol Res (2013) 0.82
Lung effector memory and activated CD4+ T cells display enhanced proliferation in surfactant protein A-deficient mice during allergen-mediated inflammation. J Immunol (2011) 0.81
FOXP3, IL-10, and TGF-β genes expression in children with IgE-dependent food allergy. J Clin Immunol (2010) 0.81
Role of childhood infection in the sequelae of H. pylori disease. Gut Microbes (2013) 0.80
Characterization of dendritic cell and regulatory T cell functions against Mycobacterium tuberculosis infection. Biomed Res Int (2013) 0.79
Cholangiocarcinoma with respect to IgG4 Reaction. Int J Hepatol (2014) 0.79
Allergic rhinitis and genetic components: focus on Toll-like receptors (TLRs) gene polymorphism. Appl Clin Genet (2010) 0.78
Genistein enhancement of respiratory allergen trimellitic anhydride-induced IgE production by adult B6C3F1 mice following in utero and postnatal exposure. Toxicol Sci (2005) 0.77
Inhaled corticosteroid use is associated with increased circulating T regulatory cells in children with asthma. Clin Mol Allergy (2013) 0.77
Effects of mycobacteria major secretion protein, Ag85B, on allergic inflammation in the lung. PLoS One (2014) 0.76
A Role for Regulatory T Cells in a Murine Model of Epicutaneous Toluene Diisocyanate Sensitization. Toxicol Sci (2016) 0.76
Immunotherapy in all aspects. Eur Arch Otorhinolaryngol (2015) 0.76
Ex vivo modulation of the Foxo1 phosphorylation state does not lead to dysfunction of T regulatory cells. PLoS One (2017) 0.75
In Utero exposure to genistein enhanced intranasal house dust mite allergen-induced respiratory sensitization in young adult B6C3F1 mice. Toxicol Lett (2016) 0.75
Interleukin-4 suppresses the cytotoxic potential of in vitro generated, adaptive regulatory CD4 T cells by down-regulation of granzyme B. Immunology (2008) 0.75
Distinct cytokine mRNA expression pattern in immunoglobulin G4-related kidney disease associated with renal cell carcinoma. Clin Kidney J (2014) 0.75
Local nasal specific immunotherapy for allergic rhinitis. Allergy Asthma Clin Immunol (2006) 0.75
A double edged sword: Schistosoma mansoni Sm29 regulates both Th1 and Th2 responses in inflammatory mucosal diseases. Mucosal Immunol (2016) 0.75
Autoimmune pancreatitis: pathogenesis, latest developments and clinical guidance. Ther Adv Chronic Dis (2014) 0.75
Regulatory T Cells in Allergy and Asthma. Front Pediatr (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet (2001) 10.92
Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 10.19
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18
Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 8.74
Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med (2001) 8.69
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 8.69
Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science (2002) 8.34
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28
Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med (2001) 7.86
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med (2002) 6.48
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 6.47
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 6.22
Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 5.46
In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med (2002) 5.28
Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol (2001) 5.11
Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol (2001) 4.58
CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med (2002) 4.56
Allergy and allergic diseases. First of two parts. N Engl J Med (2001) 4.33
Asthma: an epidemic of dysregulated immunity. Nat Immunol (2002) 4.00
Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 3.91
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 3.83
Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med (2002) 3.80
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol (2002) 3.71
Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood (2001) 3.66
Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol (2001) 3.53
IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol (2004) 3.46
A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol (1999) 3.42
Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med (2002) 3.31
Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet (2001) 3.06
Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet (2004) 3.05
CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol (2000) 2.98
Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science (1994) 2.66
IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol (2003) 2.62
Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med (2002) 2.51
Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am J Respir Crit Care Med (2003) 2.46
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ (1991) 2.32
T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol (2000) 2.22
Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A (1996) 2.21
Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest (2004) 2.20
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol (2004) 2.10
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med (2004) 1.96
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol (2003) 1.91
T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production. J Exp Med (1999) 1.85
Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol (1993) 1.82
Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy (1997) 1.80
Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol (1999) 1.78
Suppressor T cells in human diseases. J Exp Med (2004) 1.73
Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med (1993) 1.71
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest (1993) 1.66
Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J Exp Med (1989) 1.65
Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A (2004) 1.62
Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy (2001) 1.61
Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J Exp Med (2001) 1.59
Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy (2001) 1.56
Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science (1992) 1.56
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol (1998) 1.52
Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med (1999) 1.48
Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol (1995) 1.47
CD4+CD25+ T cells regulate airway eosinophilic inflammation by modulating the Th2 cell phenotype. J Immunol (2004) 1.45
Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol (2003) 1.42
Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol (1999) 1.42
Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol (2003) 1.34
Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood (2003) 1.32
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 1.29
Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol (1998) 1.28
Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. J Immunol (2003) 1.27
Mouse models of allergic airway disease. Adv Immunol (2001) 1.26
Twenty-first century Foxp3. Nat Immunol (2003) 1.25
Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol (1997) 1.22
A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med (2002) 1.21
Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells. J Immunol (2004) 1.19
Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am J Respir Crit Care Med (2001) 1.19
Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol (1996) 1.16
Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol (2003) 1.16
Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy (2005) 1.12
Cow's milk-specific T-cell reactivity of children with and without persistent cow's milk allergy: key role for IL-10. J Allergy Clin Immunol (2004) 1.11
Th-2 cytokines in allergic disease. Br Med Bull (2000) 1.10
Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci U S A (1997) 1.10
Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol (2001) 1.09
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am J Respir Crit Care Med (2003) 2.46
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85
Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med (2009) 1.73
Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol (2006) 1.68
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood (2013) 1.44
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med (2005) 1.24
Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol (2011) 1.23
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol (2007) 1.22
Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets (2008) 1.15
The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12
Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12
Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09
Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08
Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08
Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol (2012) 1.07
Immunotherapy with peptides. Allergy (2011) 1.07
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02
Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am (2006) 0.97
IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96
Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95
Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92
NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91
One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89
Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am (2011) 0.88
Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol (2004) 0.87
Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med (2002) 0.86
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res (2006) 0.85
Peptide-based vaccination: where do we stand? Curr Opin Allergy Clin Immunol (2005) 0.84
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol (2010) 0.84
Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax (2013) 0.83
CXCR1+CD4+ T cells in human allergic disease. J Immunol (2004) 0.83
Postnasal drip and chronic cough: An open interventional study. Respir Med (2009) 0.82
Tobacco industry lobbyists and their health-care clients. Lancet (2013) 0.82
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol (2012) 0.82
Peptide-based vaccines in the treatment of specific allergy. Curr Drug Targets Inflamm Allergy (2002) 0.81
Immunological responses to allergen immunotherapy. Clin Allergy Immunol (2004) 0.81
Investigating T cell activation and tolerance in vivo: peptide challenge in allergic asthmatics. Cytokine (2004) 0.81
Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol (2012) 0.81
Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am (2011) 0.81
Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol (2013) 0.80
Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev Vaccines (2005) 0.80
The potential of peptide immunotherapy in allergy and asthma. Curr Allergy Asthma Rep (2002) 0.79
Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79
Immune mechanisms of sublingual immunotherapy: are oral Langerhans cells the masters of tolerance? J Allergy Clin Immunol (2010) 0.78
Allergen immunotherapy with cat allergen peptides. Springer Semin Immunopathol (2003) 0.78
Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep (2002) 0.78
Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. Thorax (2007) 0.78
Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77
Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? J Allergy Clin Immunol (2009) 0.77
Peptide immunotherapy for allergic disease. Expert Opin Biol Ther (2003) 0.76
Immunomodulatory treatment strategies for allergic diseases. Curr Drug Targets Inflamm Allergy (2003) 0.76
Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol (2008) 0.76
T Lymphocyte responses to nonpolymorphic HLA-derived peptides are associated with chronic renal allograft dysfunction. Transplantation (2011) 0.76
Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med (2006) 0.75
Peptide therapy and asthma. Am J Respir Crit Care Med (2004) 0.75
Treatment of seasonal allergic rhinitis: desensitisation for hay fever works. BMJ (2003) 0.75
Perennial rhinitis. BMJ (2007) 0.75
Silk contact anaphylaxis. Contact Dermatitis (2014) 0.75
Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.75
Chronic graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptides. Transplantation (2010) 0.75
Allergen injection immunotherapy. Clin Allergy Immunol (2002) 0.75
Tradition and innovation: finding the right balance. J Allergy Clin Immunol (2007) 0.75
Biomarkers of tolerance in response to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess (2013) 0.75